N-(2-hydroxy-4-nitro-5-chlorophenyl)-N'-(phenyl)urea | 117745-34-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-(2-hydroxy-4-nitro-5-chlorophenyl)-N'-(phenyl)urea
• 英文别名: N-(5-Chloro-2-hydroxy-4-nitrophenyl)-N'-phenylurea；1-(5-Chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea
• CAS: 117745-34-3
• 化学式: C₁₃H₁₀ClN₃O₄
• 分子量: 307.693
• InChiKey: ASMCVDDUQQZBFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
  申请人：BAYER CORPORATION

  公开号：US20040102636A1

  公开（公告）日：2004-05-27

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗细胞因子介导的疾病和蛋白酶酶介导的疾病，以及用于该疗法的药物组合物。
• [EN] IL-8 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS D'IL-8
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1996025157A1

  公开（公告）日：1996-08-22

  (EN) This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).(FR) Cette invention se rapporte à une nouvelle utilisation des urées phényliques dans le traitement d'états pathologiques dont le médiateur est la chimiokine, appelée interleukine-8 (IL-8).

  该发明涉及苯基脲在治疗由趋化因子Interleukin-8 (IL-8)介导的疾病状态中的新用途。(中文翻译)
• IL-8 receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20020128321A1

  公开（公告）日：2002-09-12

  This invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

  本发明涉及新型化合物和苯基脲在治疗由趋化因子Interleukin-8（IL-8）介导的疾病状态中的新用途。
• INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
  申请人：Miller Scott

  公开号：US20090093526A1

  公开（公告）日：2009-04-09

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

  本发明涉及使用一组芳基脲类化合物治疗细胞因子介导的疾病和蛋白酶酶介导的疾病，以及用于该疗法的制药组合物。
• Methods for promoting survival of transplanted tissues and cells
  申请人：Johnson & Johnson Vision Care, Inc.

  公开号：EP1676574A2

  公开（公告）日：2006-07-05

  Methods for enhancing the survival of a cell, tissue, or organ transplanted into a recipient comprising contacting the cell, tissue, or organ graft with an agent that decreases the rate of coagulation on the transplanted cell, tissue or organ are disclosed. The agent is one that acts by reducing the amount or activity of tissue factor (TF) on the donor tissue, such as a p38 MAPK inhibitor, a JNK inhibitor, a p38 MAPK/JNK dual inhibitor and a TF antagonist. Cells, tissues and organs treated with those agents are also disclosed.

  本发明公开了提高移植到受者体内的细胞、组织或器官存活率的方法，该方法包括使细胞、组织或器官移植体与一种能降低移植细胞、组织或器官凝血率的药剂接触。这种药剂通过减少供体组织上组织因子（TF）的数量或活性发挥作用，如 p38 MAPK 抑制剂、JNK 抑制剂、p38 MAPK/JNK 双抑制剂和 TF 拮抗剂。还公开了用这些制剂处理的细胞、组织和器官。